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The etiology of cerebral ischemia associated with AF is often assumed to be embolism of left atrial thrombi. However, nonvalvular AF is usually related to ischemic or other heart disease, most often in elderly patients with risk factors for cerebrovascular athero sclerosis. Thromboembolism from coexistent left ven tricular disease or cerebrovascular disease may ac count for many strokes in NVAF patients. Thus, in some portion of patients, NVAF is only a marker of other cardiac and cerebrovascular diseases which cause ischemic stroke. The relative prevalence of these mechanisms in AF patients with stroke is uncertain and often difficult to define in individual patients. 8 It is perhaps not so surprising that patients with chronic NVAF embolize, but that they do so intermit tently. Often embolic episodes are separated by years, in other instances by only hours. 5 The mechanisms responsible for formation and intermittent emboliza tion of left atrial clot in these patients are uncertain. Between 2-15% of NVAF patients with embolic stroke have been reported to experience early recurrent emboli within two weeks of the initial embolic The role of immediate anticoagulation to prevent early recurrence of embolic brain infarction is unclear, because of the fear of creating hemorrhagic infarction from initially pale infarction. 8 Given the frequency and importance of NVAF-asso ciated stroke in clinical practice, the natural history has received relatively scant attention. '• 4 ' 5 - 9 We retrospec tively review the clinical features of 56 patients with NVAF and cerebral infarction to estimate the fraction of NVAF-associated stroke that is embolic and to de termine the early recurrence rate following initial em bolism.
Methods
Patients were identified by cross-indexing discharge diagnostic codes for atrial fibrillation (ICD-9 427.31) and cerebral infarction and/or embolism (ICD-9 434.1) for the years 1978-1981 for inpatients at two referral-based hospitals. Each chart was reviewed in detail by one of the authors. Patients with clinical or echocardiographic evidence of valvular heart disease (rheumatic heart disease, prosthetic valve, mitral valve prolapse) were excluded.
Embolic versus Nonembolic Stroke
Classification of the cause of stroke as cardiogenic embolism versus cerebrovascular disease is imperfect, even arbitrary, on clinical grounds. Because of the age and concomitent hypertension of these patients, it can not be assumed that all or even most strokes associated with nonvalvular atrial fibrillation are on the basis of cardiogenic embolism. Clinical criteria were em ployed in an attempt to separate NVAF patients into embolic versus nonembolic mechanisms. This algo rithm is based primarily on the use of abrupt onset of maximal neurologic deficit in an awake patient to char acterize cardiogenic embolism. Although non-sudden onset of embolic stroke can occur in a minority of patients with cardiogenic embolism, progressive or stuttering deficits are far more likely to be on the basis of mechanisms other than cardiogenic embolism and, in the absence of other data, such strokes were classi fied as probably nonembolic. Atrial fibrillation is often associated with other car diac disease (myocardial infarction, decompensated heart failure) which may result in cerebral embolism independently of left atrial thrombi. Because of poten tial differences in rate of early recurrent embolism as sociated with underlying heart disease, patients were divided into three subtypes based on clinical data: I. AF attributed to ischemic-hypertensive cardiovas cular disease but without transmural MI, decompen sated congestive failure or other recognized sources of embolism. Chronic, persistent "idiopathic" AF in pa tients over 50 were included.
II. AF associated with ischemic heart disease with transmural MI, ventricular aneurysm and/or conges tive heart failure. III. AF associated with other specific, nonischemic heart disease (eg, thyrotoxicosis, pre-excitation syn drome) or idiopathic AF in patients under 50.
Atrial fibrillation was further subdivided into con stant versus intermittent. If NVAF was observed to spontaneously convert to other rhythms within one year before or after stroke, it was classified as intermit tent.
Stroke size was estimated using clinical criteria based on neurologic deficit and CT data, as described elsewhere. 8 Eighteen patients received immediate anti coagulation with heparin or Coumadin in a nonconsecutive, nonrandomized manner at the discretion of their attending physicians.
Results

Group A -Embolic Stroke
Thirty-five strokes (63%) were categorized as prob ably embolic (Group A, Tables 1 and 2 Given the uncertainties of clinical categorization into embolic versus nonembolic stroke, minimum val ues for early recurrent embolism are obtained by con sidering all patients. Recurrent embolism after initial stroke occurred in 3 patients -8% of those who were not immediately anticoagulated.
Including the five patients with probable ernbolic events shortly before the brain embolism that lead to study inclusion, 8 of 40 (20%) of all NVAF patients with initial systemic or cerebral embolism who are not immediately anticoagulated re-embolized within two weeks. In these 8 patients, the initial embolus was systemic in 5 patients and Cerebral in 3 patients; the second embolus was cerebral in 6 patients and system ic in 2 patients. In patients with more than one embo lus, 56% were to the brain. Distinguishing em bolic from nonembolic mechanisms is a common clini cal dilemma and has implications for longterm man agement. In the Harvard Cooperative Stroke Registry < 74% of infarctions in patients with atrial fibrillation were categorized as embolic." Sage and VanUitert 9 reported that 97% of 145 patients with NVAF and stroke had cardiogenic embolism as the likely cause. In our retrospective review, 63% of infarctions associat ed with NVAF were classified as embolic. The clinical criteria used in the above studies to distinguish embolic from nopembolic infarction are probably imprecise. In our methodology, we used the nonsudden onset of symptoms to categorize patients as probably nonem bolic (Group B) in seven instances. Although nonsud den onset Of cardiogenic embolic stroke is well estab lished, a stuttering or fluctuating evolution heralds thrombotic stroke "in the great majority of cases." 15 Epidemiologic data confirm that many strokes asso ciated with NVAF are nonembolic. As NVAF occurs in 3-5% of the elderly 6 -7 but 9-25% of all patients with brain infarctions, 6 , "• 9 With the advent of low risk diagnostic investi gations (digital subtraction angiography, real-time ca rotid Doppler ultrasound), further studies may well be warranted to define stroke mechanism in these pa tients. Cardiac computed tomography may occasional ly confirm the existence of atrial thrombus ( fig. 2) .
Immediate anticoagulation of cardiogenic brain em bolism has been controversial and the subject of sever al recent studies. 8 The risk of early recurrent embolism must be balanced against the risk of hemorrhagic trans formation of pale infarction due to anticoagulation. The risk of early recurrent embolism (within two weeks) may depend on the type of cardiac source. Fisher reported an 8% prevalence of early re-embolism but his patient population included a minority with valvular disease and immediate therapy was not speci fied. 5 Sage and VanUitert reported only 2% of NVAF patients who were survivors of initial hospitalization had recurrence within 3 months, but the early recur rence rate in the 38% who did not survive initial hospi talization was not given. 9 Darling et al. reported a 20% early recurrence rate, but his series antedated echocar diography and many patients undoubtedly had occult valvular disease. 10 There were two patients among 13 NVAF who did not receive immediate anticoagulation in the Cerebral Embolism Study Group's data who experienced recurrent embolism within two weeks of initial embolism/ Our retrospective results yield a maximum and minimum figure for early recurrence, depending upon inclusion of embolic events occurring just prior to the marker stroke. Three early recurrent emboli occurred in the 16 patients with probable embolism who re ceived no immediate treatment (figure 1). Five addi tional emboli occurred within 11 days of the marker stroke in patients who were not immediately anticoag ulated at the time of initial embolism. A maximum figure for early recurrent embolism in NVAF patients who were not immediately anticoagulated at the time of initial embolism is 20% (8 of 40). A minimum figure, considering only prospective embolic events from marker stroke in all NVAF patients (Groups A, B and C) who were not immediately anticoagulated is 8% (3 of 38).
The efficacy of immediate anticoagulation in pre vention of early recurrent embolism is suggested by aggregate data which show no episodes of early reembolism in 29 patients who were immediately anticoag ulated. 8 There were no major hemorrhagic complications in these patients, although they were nonconsecutive and nonrandomly selected for immediate anticoagulation at the discretion of their attending physician in this retrospective study.
In this series, over half of all patients with NVAF and stroke had constant, not intermittent, NVAF. It is possible, however, that many patients with brief epi sodes of sinus rhythm were misclassified. The Framingham study reported that 86% (37 of 43) of pa tients with NVAF and stroke had chronic, persistent atrial fibrillation.
14 Most of our patients had no other cardiac sources of stroke except NVAF (Type 1). All instances of early recurrent embolism occurred in Type 1 patients.
Two-dimensional echocardiography in NVAF pa tients with stroke has shown important, unsuspected abnormalities predisposing to cardiogenic embolism in 10-16%. 8 12 Most of our patients had only M-mode echocardiography. Anecdotally, mitral annulus calci fication was detected echocardiographically in three patients (9% of those who underwent echocardiog raphy) . Of patients who were over age 65, mitral annu lus calcification was present in 14% (3 of 23) of echo cardiograms.
We conclude that 25-35% of patients with NVAF and stroke have cerebrovascular disease as the cause of brain ischemia. Embolic stroke in NVAF occurs in patients with chronic, persistent atrial fibrillation with out other cardiac embolic sources. Early recurrent em bolism occurs in about 15% of NVAF patients who are not immediately anticoagulated at the time of the initial embolus. Recent development of safe, noninvasive techniques (e.g., digital angiography, real-time Dopp ler scanning, cardiac CT) should allow better defini tion of stroke mechanism in these relatively elderly patients, allowing more specific therapy.
